BioTime Announces Update to Third Quarter 2018 Financial Results Conference Call
Call moved to 5:30 a.m. PT / 8:30 a.m. ET on November 8th,
ALAMEDA, Calif.--(BUSINESS WIRE)--Nov. 6, 2018--
Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology
company focused on degenerative diseases, today announced that it has
changed the time of its previously announced conference call to discuss
its third quarter 2018 financial and operating results. BioTime
management will be hosting the call on Thursday, November 8th,
2018, at 8:30 a.m. Eastern Time/5:30 a.m. Pacific Time.
Interested parties may access the conference call by dialing (866)
888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere
outside the U.S. and should request the “BioTime Inc. Call”. A live
webcast of the conference call will be available online in the Investors
section of BioTime’s website. A replay of the webcast will be available
on BioTime’s website for 30 days and a telephone replay will be
available through November 15th, 2018, by dialing (855)
859-2056 from the U.S. and Canada and (404) 537-3406 from elsewhere
outside the U.S. and entering conference ID number 8658619.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on the
development and commercialization of novel therapies for the treatment
of degenerative diseases. BioTime’s pipeline is based on two platform
technologies which encompass cell replacement and cell/drug delivery.
BioTime’s lead cell replacement product candidate is OpRegen®,
a retinal pigment epithelium transplant therapy in Phase 2 development
for the treatment of dry age-related macular degeneration, the leading
cause of blindness in the developed world. BioTime’s lead cell delivery
clinical program is Renevia®, an investigational medical
device being developed as an alternative for whole adipose tissue
transfer procedures. BioTime also has significant equity holdings in two
publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE
American: AST) and OncoCyte Corporation (NYSE American: OCX), and a
private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the
symbol BTX. For more information, please visit www.biotime.com or
connect with the company on Twitter,
To receive ongoing BioTime corporate communications, please click on the
following link to join the Company’s email alert list: http://news.biotime.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181106005939/en/
Source: BioTime Inc.
BioTime Inc. IR
Ioana C. Hone, 510-871-4188
Gitanjali Jain Ogawa, 646-378-2949